Exane Derivatives Cara Therapeutics, Inc. Transaction History

Exane Derivatives

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 12, 2022	SELL	$7.45 - $13.84 $6,511 - $12,096	-874 Closed	0 $0
Q2 2021 Jul 28, 2021	SELL	$12.38 - $29.19 $2,624 - $6,188	-212 Reduced 19.52%	874 $12,000
Q1 2021 Apr 30, 2021	SELL	$15.07 - $21.71 $7,761 - $11,180	-515 Reduced 32.17%	1,086 $23,000
Q1 2020 Apr 17, 2020	SELL	$9.12 - $17.78 $58,988 - $115,001	-6,468 Reduced 80.16%	1,601 $21,000
Q4 2019 Jan 22, 2020	SELL	$16.11 - $25.98 $160,213 - $258,371	-9,945 Reduced 55.21%	8,069 $129,000

Q3 2019 Oct 15, 2019	SELL	$18.28 - $26.91 $36,541 - $53,793	-1,999 Reduced 9.99%	18,014 $329,000
Q2 2019 Jul 12, 2019	BUY	$17.68 - $21.57 $233,835 - $285,284	13,226 Added 194.87%	20,013 $0
Q1 2019 Apr 24, 2019	SELL	$14.41 - $19.64 $5,951 - $8,111	-413 Reduced 5.74%	6,787 $0
Q2 2018 Jul 19, 2018	BUY	$11.6 - $19.27 $83,520 - $138,744	7,200 New	7,200 $0

102

21.5M

50K

Ticker CARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,725,900
Market Cap $14M
Description
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...

Get notified when there are updates to the investment portfolio of Exane Derivatives, based on Form 13F filings with the SEC.

Stay updated on Exane Derivatives with notifications on news.